top of page
Create Your First Project
Start adding your projects to your portfolio. Click on "Manage Projects" to get started
Zymeworks
Date
November 2022
Zymeworks’ lead product candidate, zanidatamab, is a HER2-targeted bispecific antibody developed using Zymeworks proprietary Azymetric™ platform. Zanidatamab is currently being evaluated as a best-in-class treatment for patients with HER2-expressing cancers, including biliary tract, gastroesophageal adenocarcinomas, breast, and other tumor types.
Entry Price: $7.47
bottom of page